- Home
- GT vs NNNN Comparison
GT vs NNNN Comparison
Compare GT & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GT
- NNNN
- Stock Information
- Founded
- GT 1898
- NNNN 2021
- Country
- GT United States
- NNNN Germany
- Employees
- GT N/A
- NNNN N/A
- Industry
- GT Automotive Aftermarket
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GT Consumer Discretionary
- NNNN Health Care
- Exchange
- GT Nasdaq
- NNNN Nasdaq
- Market Cap
- GT 2.4B
- NNNN 2.2B
- IPO Year
- GT N/A
- NNNN 2025
- Fundamental
- Price
- GT $6.85
- NNNN $28.00
- Analyst Decision
- GT Buy
- NNNN
- Analyst Count
- GT 4
- NNNN 0
- Target Price
- GT $12.13
- NNNN N/A
- AVG Volume (30 Days)
- GT 9.7M
- NNNN 77.8K
- Earning Date
- GT 11-03-2025
- NNNN 10-31-2025
- Dividend Yield
- GT N/A
- NNNN N/A
- EPS Growth
- GT N/A
- NNNN N/A
- EPS
- GT 1.47
- NNNN 0.06
- Revenue
- GT $18,489,000,000.00
- NNNN $8,185,146.00
- Revenue This Year
- GT N/A
- NNNN N/A
- Revenue Next Year
- GT $0.65
- NNNN N/A
- P/E Ratio
- GT $4.65
- NNNN $536.42
- Revenue Growth
- GT N/A
- NNNN 21.95
- 52 Week Low
- GT $6.51
- NNNN $5.18
- 52 Week High
- GT $12.03
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- GT 23.65
- NNNN 38.97
- Support Level
- GT $6.51
- NNNN $26.05
- Resistance Level
- GT $6.89
- NNNN $30.90
- Average True Range (ATR)
- GT 0.22
- NNNN 5.65
- MACD
- GT -0.03
- NNNN 0.03
- Stochastic Oscillator
- GT 21.96
- NNNN 20.62
About GT The Goodyear Tire & Rubber Company
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.